Phase 1 Trial of Ipilimumab and GVAX in Patients With Metastatic Castration-resistant Prostate Cancer

Inclusion Criteria: * Males age 18-80 years * Histologic diagnosis of adenocarcinoma of the prostate * Metastatic prostate cancer deemed to be unresponsive or refractory to hormone therapy * Detectable metastases by bone scan, CT scan or MRI * Two consecutive rising PSA values obtained at least two weeks apart and both obtained at least 4-6 weeks after discontinuation of hormone therapy. Second PSA value must be \> 5.0 ng/mL. LHRH agonist should not be discontinued. * Testosterone \< 50 ng/dL. Must have had orchiectomy or is currently receiving an LHRH agonist. * WBC \> 3.0 x 109/L, ANC \> 1.5 x 109/L, hemoglobin \> 6.2 mmol/L, and platelets \> 100 x 109/L * Serum creatinine \< 177 umol/L Bilirubin \< 1.5 times the upper limit of normal AST \< 3 times the upper limit of normal * ECOG performance status 0-2 * Life expectancy of at least 6 months * If sexually active, willing to use barrier contraception during the treatment phase of the protocol * The ability to understand and willingness to sign a written informed consent Exclusion Criteria: * Transitional cell, small cell, neuroendocrine, or squamous cell prostate cancer * Bone pain severe enough to require routine narcotic analgesia use * Clinical evidence of brain metastases or history of brain metastases * Seropositive for HIV, Hepatitis B antigen positive and/or Hepatitis C viremic * Prior chemotherapy or immunotherapy for prostate cancer * Radiation therapy within 4 weeks of the first treatment * Surgery within 4 weeks of the first treatment. Must have recovered from all side effects. * Flutamide within 4 weeks of the first treatment Megesterol acetate (Megace), finasteride (Proscar), bicalutamide (Casodex),nilutamide, aminoglutethimide, ketoconazole or diethylstilbestrol within 6 weeks of the first treatment. * Systemic corticosteroid use within 4 weeks of the first treatment * History of autoimmune disease * History of another malignancy, except for the following: adequately treated basal cell or squamous cell skin cancer, superficial bladder cancer, adequately treated Stage I or II cancer currently in complete remission or any other cancer that has been in complete remission for at least 5 years